@Denial
I don't think that necessarily means they'd bundle MPS and OA together in those regions, of course they may, but I don't think these recent results make it more likely. The target population size hasn't changed. The study proved safety with and pointed towards efficacy in a tiny sample size. You speak with so much certainty as if the company has told us is what they will do - I don't think this now confirms that they'd make it part of a regional licensing package MPS + OA.
Ann: PAR Appoints Business Development Consultant, page-112
-
- There are more pages in this discussion • 216 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
25.0¢ |
Change
0.005(2.04%) |
Mkt cap ! $87.44M | |||
| Open | High | Low | Value | Volume |
| 25.0¢ | 25.0¢ | 24.5¢ | $46.64K | 187.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 136564 | 25.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 25.5¢ | 54541 | 4 |
View Market Depth
| Last trade - 13.33pm 25/06/2024 (20 minute delay) ? |
| PAR (ASX) Chart |